Group items tagged

44th Annual Vascular and Endovascular Issues, Techniques, Horizons (VEITH) Symposium is organized by Cleveland Clinic and would be held during Nov 14 - 18, 2017 at New York Hilton Midtown, New York, United States of America. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques. Objectives : Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to: * Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease * Summarize the impact of data on therapeutic advances for stroke and carotid disease management * Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease * Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care * Summarize recent data on treatment advances for venous disease and explain their clinical implications * Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors

American Association for Hand Surgery (AAHS) Annual Meeting is organized by American Association for Hand Surgery (AAHS) and would be held during Jan 10 - 13, 2018 at El Conquistador, A Waldorf Astoria Resort, Fajardo, Puerto Rico, United States Of America. The target audience for this medical event for health care professionals involved in the assessment and management of a wide variety of common and complex conditions of the hand and upper limb. This CME Conference has been approved with a maximum of 30 AMA PRA Category 1 Credits. Conference Objectives are : Following completion of this activity, participants will be able to: * Develop relationships and mentoring that lead to successful hand research and contributions to better patient outcomes. * Understand the new landscape of medicine leading to better patient care through the use of social media, the internet and understating new reimbursement models. * Discuss clinical and basic scientific research on hand and upper extremity problems. * Integrate principles of hand therapy with surgical management of hand and upper extremity problems. * Evaluate surgical and nonsurgical principles of managing common hand and upper extremity problems. * Compare the intellectual discourses through an integrated program with the related surgical societies (ASRM and ASPN) and resolve conflicts. * Implement enhanced management of fractures, arthritis and congenital problems. * Compare clinical and nonclinical hand therapy issues for a variety of hand problems and fractures.

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 2, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

American Psychiatric Association (APA) 171th Annual Meeting is organized by American Psychiatric Association (APA) and would be held during May 5 - 9, 2018 at New York, United States of America.

Transcatheter Cardiovascular Therapeutics (TCT) is organized by CardioVascular Research Foundation (CRF) and would be held during Oct 29 - Nov 02, 2017 at Colorado Convention Center, Denver, Colorado, United States of America. The target audience for this medical event for interventional cardiologists, radiologists, clinical cardiologists, scientists, vascular medicine specialists, cardiac and vascular surgeons, nurse practitioners, cath lab technicians, and other healthcare professionals with a special interest in the field of interventional and vascular medicine. Activity Goals : The overall goal of this activity is to improve the competence and performance of our target audience by delivering cutting-edge educational content that showcases the latest advances in current therapies and clinical research. We hope that our longstanding commitment to lifesaving innovation will translate into improved patient care. Learning Objectives : By the end of the symposium, participants should be able to: * Apply the results from important clinical trials and evidence-based medicine to guide the management of patients with atherosclerosis and structural heart disease * Incorporate new interventional technologies and procedures into the care of patients with complex coronary and endovascular disease * Integrate advances in diagnostic evaluation and therapeutics into the treatment of patients with carotid and peripheral arterial disease * Implement appropriate pharmacologic management in the care of patients undergoing diagnostic arteriography and interventional therapies before, during, and after catheterization * Identify new interventional technologies and propose appropriate applications for patients with cardiovascular disease

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.

American College of Emergency Physicians (ACEP) Scientific Assembly is organized by American College of Emergency Physicians (ACEP) and would be held during Oct 29 - Nov 01, 2017 at Walter E. Washington Convention Center, Washington, Dist of Col, United States of America. The target audience for this medical event for Emergency Physicians, Emergency Nurses, Nurse Practitioners, Residents and Fellows, Medical Students. This cme conference has been approved with a maximum of 29 AMA PRA Category 1 Credits. This Course will consist of clinical, as well as essential management and risk management tools to aid in your day-to-day practice. With educational courses, skills labs and workshops - ACEP17 is the best source for your emergency medicine education needs! Conference Objectives are : * Abdominal Disorders * Airway, Anesthesia, Analgesia * Cardiovascular * Career Advancement Through Teaching * Critical Care * Critical ED Management * Dematologic Disorders * Emergency Imaging * Head & Neck Disorders * Health Policy * Hematologic Disorders * Infectious Disease * Knowledge Translation * Maintenance of Certification * Metabolic and Endocrine Disorders * Neurology * New Technology * Orthopedics and Sports Medicine * Pediatric Disorders * Prehospital / Disaster Medicine * Professional Skills * Pulmonary Disorders * Risk Management / ED and Law * Toxicology / Environmental * Trauma * Urologic and OB/GYN ACEP17 is the must attend event for anyone engaged in the practice of emergency medicine, including : * Emergency Physicians * Nurse Practitioners * Residents * Medical Students * Physician Assistant * Emergency Department Medical Directors * Hospital Administrators * EMTs/Paramedics

Too many carbs, not fats, may be the culprit in raising risk of premature death, according to a study published online Aug. 29 in the The Lancet to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain. Mahshid Dehghan, Ph.D., an investigator with the Population Health Research Institute at McMaster University in Hamilton, Canada, and colleagues tracked the diet and health of 135,335 people, aged 35 to 70, from 18 countries around the world, to gain a global perspective on the health effects of diet. Participants provided detailed information on their social and economic status, lifestyle, medical history, and current health. They also completed a questionnaire on their regular diet, which researchers used to calculate their average daily calories from fats, carbohydrates, and proteins. The research team then tracked the participants' health for about seven years on average, with follow-up visits at least every three years. The investigators found that high-carbohydrate diets are common, with more than half of the people deriving 70 percent of their daily calories from carbs. People with a high fat intake -- about 35 percent of their daily diet -- had a 23 percent lower risk of early death and 18 percent lower risk of stroke compared to people who ate less fat. The researchers also noted that a very low intake of saturated fats (below 3 percent of daily diet) was associated with a higher risk of death in the study, compared to diets containing up to 13 percent daily. At the same time, high-carb diets -- containing an average 77 percent carbohydrates -- were associated with a 28 percent increased risk of death versus low-carb diets. "The study showed that contrary to popular belief, increased consumption of dietary fats is associated with a lower risk of death," Dehghan told HealthDay. "We found no evidence that below 10 percent of energy by saturated fat is beneficial, and going below 7 percent may even be har

KT3: Clinical concept and advanced whole body application is organized by Texas Children's Hospital and will be held on Jan 26, 2018 at Texas Children's Hospital, Houston, Texas, USA. This CME Conference has been approved for a maximum of 8 CCUs or 8 contact hours. Course Description : The KT3 course combines the Kinesio Taping Method foundational concepts of KT1&KT2 with advanced clinical concepts. The course provides lab time for attendees to practice their skills on the new concepts through a variety of clinical applications. The KT3 course is designed to allow the Certified Kinesio Taping Instructor (CKTI) to cater specific clinical applications to address specific professions. Upon completion of this course and prerequisite KT1&KT2 seminar, attendees will be eligible to request and take the exam to become a Certified Kinesio Taping Practitioner (CKTP). Note: Students can request to take the exam but will not be eligible to receive a CKTP certificate until they graduate. Course Objectives are : * Review the basic concepts of the Kinesio Taping Method * Explain and apply advanced concepts of the Kinesio Taping Method * Review epidermis, dermis, and fascial anatomy as it is related to Kinesio Taping * Utilize and demonstrate application skills in guided laboratory sessions * Apply the Kinesio Taping Method to stimulate epidermis, dermis, and fascial response * Apply advanced clinical taping techniques for treatment of the spine, neurological conditions, and upper/lower extremity dysfunction

Nurse Anesthesia Seminars : Newport Mansions Fall Foliage in New England 2018 Anesthesia Encore Symposium is organized by Encore Symposiums and will be held during Oct 01 - 04, 2018 at Hotel Viking, Newport, Rhode Island, United States of America.

Most physicians on Twitter with a financial conflict of interest (FCOI) and frequent tweets mention specific drugs for which they have a conflict, according to a study published in the September issue of The Lancet Haematology. Victoria Kaestner, from the Oregon Health & Science University in Portland, and colleagues examined whether conflicted physicians tweet about specific products for which they have a FCOI. A total of 156 physicians who tweeted a median of 584 times were included, with a 2014 median general payment totaling $13,600. The researchers found that 81 percent of the physicians mentioned at least one drug from a company for which they had a FCOI and 88 percent mentioned at least one drug for which they did not have an FCOI. Fifty-two percent of the 4,358 total drug mentions regarded conflicted drugs. Only 1.3 percent of the physicians included a disclosure relating to their payment; these were in their twitter biography. Conflicted tweets were more likely to be positive, similarly likely to be neutral, and less likely to be negative, compared with tweets about non-conflicted drugs coded at random. "Our results raise the concern that financial conflict of interest must be considered with the growing use of social media to discuss cancer products and practices, as well as policies regarding disclosure, divesture, audit, and recusal may be considered," the authors write.

More than 78 percent of health care personnel (HCP) and 53.6 percent of pregnant women received influenza vaccination during the 2016-2017 influenza season, according to two studies published in the Sept. 29 issue of Morbidity and Mortality Weekly Report. Carla L. Black, Ph.D., from the U.S. Centers for Disease Control and Prevention (CDC), and colleagues surveyed 2,438 HCP to estimate influenza vaccination coverage. The researchers found that during the 2016-2017 season, 78.6 percent of survey respondents reported receiving vaccination, similar to reported coverage in the previous three seasons. Coverage was highest for those working in hospitals compared with those working in ambulatory or long-term-care settings (92.3 versus 76.1 and 68 percent) and for those who were required by their employer to be vaccinated (96.7 percent), as in previous seasons. Helen Ding, M.D., from the CDC, and colleagues surveyed 1,893 women pregnant at any time during October 2016 to January 2017. The researchers found that 53.6 percent of respondents reported having received influenza vaccination before or during pregnancy (16.2 and 37.4 percent, respectively); this was similar to coverage during the previous four influenza seasons. Overall, 67.3, 11.9, and 20.7 percent of women reported receiving a provider offer for influenza vaccination, receiving a recommendation but no offer, and receiving no recommendation, respectively, similar to the previous influenza season; influenza vaccination coverage was 70.5, 43.7, and 14.8 percent, respectively, among these women.

A Clinical Trial Application (CTA) is submitted to regulatory authority (Drugs Controller General of India) to seek approval for conduct of a clinical trial in India. Form 44 is an application made for grant of permission to import or manufacture a new drug or to undertake Clinical Trial.

Conjugated linoleic acid (CLA) supplementation is associated with an increase in serum C-reactive protein (CRP) concentration, according to a review and meta-analysis published online May 29 in Cardiovascular Therapeutics. Mohsen Mazidi, Ph.D., from the Chinese Academy of Sciences in Beijing, and colleagues conducted a systematic review and meta-analysis to examine the impact of CLA supplementation on serum CRP. Data were included from 14 studies. The researchers found that following supplementation with CLAs there was a significant increase in serum CRP concentrations (weighted mean difference, 0.63 mg/dL; 95 percent confidence interval, 0.13 to 1.13; heterogeneity P = 0.026); these findings were robust in sensitivity analyses. The changes in serum CRP levels were found to be independent of CLA supplementation dosage (slope, −0.02; 95 percent confidence interval, −0.10 to 0.12; P = 0.889) or follow-up duration (slope, 0.271; 95 percent confidence interval, −0.05 to 0.59; P = 0.098). "This meta-analysis suggests that CLA supplementation is associated with an increase in plasma CRP concentrations and a reduction in serum adiponectin concentrations, which indicates that CLA supplements have a pro-inflammatory effect," the authors write.

eMedEvents is recognized as a Winner of eHealthcare Leadership Awards at a special presentation on November 11, 2015 at the 19th Annual Healthcare Internet Conference in Orlando, Florida. eMedEvents won the Best Overall Internet Site-Silver award under physician focused category for an outstanding website. Judges reviewed eMedEvents based on a proprietary multi-point standard of Internet excellence. The Best Overall Internet Site category had to meet more than 40 factors. Ms. Priya Korrapati, CEO of eMedEvents, has said, "We passionately believe in building a technology empowered platform that helps healthcare professionals and provide tools to find medical conferences that fits each physician's unique CME needs" on winning the prestigious award. The eHealthcare Leadership Awards 2015 has received tremendous response with over 1000 entries competing in 15 different categories and diverse healthcare backgrounds. The awards highlight the role played by the Internet in helping healthcare organizations achieve their objectives. The awards also celebrate the hard work that lies underneath each of the winning websites and digital communications initiatives. About eMedEvents eMedEvents is a leading website with most comprehensive database of medical conferences for physicians to discover medical conferences that fit with their unique needs such as CME credits, Location preferences and Board reviews. With over 6000 medical conferences 2015 to choose from, the website is a perfect location to find any medical conference in multiple medical specialties across the globe. About eHealthcare Leadership awards The Healthcare Internet Conference is a popular event that brings together the leaders from various disciplines of the healthcare industry to learn, collaborate and celebrate best practices. The conference aims at helping the healthcare leaders with the ever growing challenges of the online world through collaboration with leading marketers, and other web based service

Dual-graft (DG) adult living donor liver transplantation (ALDLT) with ABO-incompatible (ABOi) and ABO-compatible (ABOc) graft combination is associated with high rates of graft survival, with no significant difference for ABOi and ABOc grafts, according to research published online July 31 in the American Journal of Transplantation. Jae Hyun Kwon, M.D., from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective review of medical records of patients who underwent ABOi DG ALDLT between 2008 and 2014. The authors also assessed the graft regeneration rate using computed tomography volumetric analysis. During a mean follow-up of 57.0 ± 22.4 months, the researchers found that the one-, three-, and five-year patient survival rate was 96.4 percent. The rate of graft survival at one-, three-, and five-years was 96.4, 94.2, and 92.0 percent, respectively; ABOc and ABOi grafts did not differ significantly (P = 0.145). No significant differences were seen between ABOc and ABOi grafts in the biliary complication rate (P = 0.195). There was no significant difference in regeneration rates for ABOi and ABOc grafts. "DG ALDLT with ABOi and ABOc graft combination seems to be a feasible option for expanding the donor pool without additional donor risks," the authors write.